IRS-19, nasal spray 20ml

Composition

Active ingredients:

the bacterial lysates 43.27 ml,

including Streptococcus pneumoniae type I1.11 ml

Streptococcus pneumoniae type II1.11 ml

Streptococcus pneumoniae type III 1/.11 ml

Streptococcus pneumoniae type V1.11 ml

Streptococcus pneumoniae type VIII1.11 ml

Streptococcus pneumoniae type XII1.11 ml

Haemophilus influenzae type B3.33 ml

Klebsiella pneumoniae ss pneumoniae6.66 ml

Staphylococcus aureus ss aureus9.99 ml of

Acinetobacter calcoaceticus3.33 ml

Moraxella catarrhalis2.22 ml

Neisseria subflava2.22 ml

Neisseria perflava2.22 ml of

Streptococcus pyogenes group A1.66 ml

Streptococcus dysgalactiae group C1.66 ml

Enterococcus faecium0.83 ml

Enterococcus faecalis0.83 ml

Streptococcus group G1.66 mg

Auxiliary substances:

glycine-4.25 g,

sodium merthiolate-no more than 1.2 mg,

nerol-based flavoring (linalool, alpha-terpineol, geraniol, methylanthranilate, limonene, geranyl acetate, linalyl acetate, diethylene glycol monoethyl ether, phenylethyl alcohol) – 12.5 mg,

purified water-up to 100 ml

Pharmacological action

Increases specific and non-specific immunity.

When sprayed, a fine aerosol is formed that covers the nasal mucosa, which leads to the rapid development of a local immune response. Specific protection is due to locally formed antibodies of the class of secretory immunoglobulins type A (IgA), which prevent the fixation and multiplication of infectious agents on the mucosa.

Non-specific immunoprotection is manifested in an increase in the phagocytic activity of macrophages, an increase in the content of lysozyme.

Indications

• treatment of acute, treatment and prevention of chronic diseases of the upper respiratory tract and bronchi;
• restoration of local immunity after viral infections;
• preparation for planned surgical intervention on ENT organs and in the postoperative period.

IRS ® 19 can be prescribed to both adults and children from 3 months of age.

Use during pregnancy and lactation

It is not recommended during pregnancy (there are no data on the potential for teratogenic or toxic effects on the fetus).

Contraindications

• autoimmune diseases;
• hypersensitivity to the components of the drug.

Side effects

Dermatological reactions:  rarely-erythema-like and eczema-like reactions; in isolated cases – thrombocytopenic purpura and erythema nodosum.

Allergic reactions:  rarely – urticaria, angioedema.

Respiratory system disorders:  rarely-asthma attacks and cough, at the beginning of treatment – rhinopharyngitis, sinusitis, laryngitis, bronchitis.

From the digestive system:  rarely (at the beginning of treatment) – nausea, vomiting, abdominal pain, diarrhea.

Other services:  rarely (at the beginning of treatment) – increased body temperature (>39°C). C) for no apparent reason.

Side effects may or may not be related to the effect of the drug. If the above symptoms occur, it is recommended to consult a doctor.

Interaction

Cases of negative interaction of the drug IRS 19 with other drugs are unknown.

In case of clinical symptoms of bacterial infection, it is possible to prescribe antibiotics against the background of continued use of IRS 19.

How to take, course of use and dosage

The drug is used intranasally by aerosol use of 1 dose (1 dose = 1 short press of the spray gun).

For the purpose of prevention, adults and children from 3 months of age are given 1 dose of the drug in each nostril 2 times / day for 2 weeks (it is recommended to start the course of treatment 2-3 weeks before the expected increase in morbidity).

For the treatment of acute and chronic diseases of the upper respiratory tract and bronchi children aged 3 months to 3 years appoint 1 dose of the drug in each nostril 2 times/day after a preliminary release of mucous discharge from the until the disappearance of symptoms of infection; children aged 3 years and adults – 1 dose in each nostril 2 to 5 times/day until the disappearance of symptoms of infection.

To restore local immunity after the flu and other respiratory viral infections, children and adults are prescribed 1 dose of the drug in each nostril 2 times a day for 2 weeks.

When preparing for planned surgical intervention and in the postoperative period, adults and children are prescribed 1 dose of the drug in each nostril 2 times / day for 2 weeks (it is recommended to start the course of treatment 1 week before the planned surgical intervention).

Rules for using the drug

For the correct functioning of the spray bottle, put the nozzle on the cylinder, center it and gently, without effort, press it. After that, the device is ready for use.

When injecting the drug, the bottle should be in a strictly vertical position, the patient should not throw his head back.

If you tilt the cylinder during injection, the propellant will leak out in a few seconds and the device will become unusable.

With regular use of the drug, it is not recommended to remove the nozzle from the bottle.

If the drug is left for a long time without use, a drop of liquid can evaporate and the resulting crystals will clog the outlet of the nozzle. This happens most often when the nozzle is removed and placed in the package with the upper end down next to the cylinder, without first washing or drying it. If there is a blockage in the nozzle, make several consecutive taps to allow the liquid to pass under the influence of excessive pressure; if there is no effect, lower the nozzle for a few minutes in warm water.

Overdose

Overdose cases are unknown

Description

Transparent colorless, sometimes with a yellowish tinge, liquid with a faint smell of Nerol-based flavoring.

Special instructions

At the beginning of treatment, reactions such as sneezing and increased nasal discharge may occur. As a rule, they are short-term in nature. If these reactions take a severe course, you should reduce the frequency of use of the drug or cancel it.

At the beginning of treatment, in rare cases, an increase in body temperature ≥39°C is possible. In this case, the drug should be discontinued. However, this condition should be distinguished from an increase in body temperature, accompanied by malaise, which may be associated with the development of diseases of the ENT organs.

In case of clinical symptoms of bacterial infection, consideration should be given to prescribing systemic antibiotics.

When prescribing IRS to 19 patients with bronchial asthma, seizures may become more frequent. In this case, it is recommended to stop treatment and not take drugs of this class in the future.

Influence on the ability to drive motor vehicles and manage mechanisms

IRS 19 does not affect the psychomotor functions associated with driving motor vehicles or managing machines and mechanisms.

Form of production

Nasal spray

Storage conditions

The drug should be stored out of the reach of children, in a strictly vertical position at a temperature not exceeding 25°C

Shelf life

3 years

Active ingredient

Bacterial lysates

Dosage Form

Spray nasal